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The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma sus-
ceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the
proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown.
Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD
mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by
vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two
components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components,
SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in
SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile
encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the
genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating
SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three
kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromo-
cytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that
germline SDHB mutations are an important cause of pheochromocytoma susceptibility.
Introduction
The pheochromocytomas are catecholamine-producing,
chromaffin tumors that arise in the adrenal medulla in
90% of cases; in the remaining 10% of cases, they devel-
op in extra-adrenal sympathetic ganglia and may be re-
ferred to as “paraganglioma.” Pheochromocytoma usu-
ally presents with hypertension. Approximately 10% of
pheochromocytoma is hereditary, and it is a well-recog-
nized feature of von Hippel–Lindau (VHL) disease (MIM
193300), of multiple-endocrine neoplasia type 2 (MIM
164761), and, rarely, of neurofibromatosis type 1 (MIM
162200) (Maher and Eng 2000). Nonsyndromic familial
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pheochromocytoma also occurs in some cases, and, al-
though a proportion of nonsyndromic familial cases have
germline VHL mutations, the molecular basis of most
nonsyndromic familial cases is unknown (Crossey et al.
1995; Neumann et al. 1995; Hofstra et al. 1996; Wood-
ward et al. 1997).
The hereditary paragangliomas belong to a group
of dominantly inherited disorders characterized by the
development of highly vascularized, nonchromaffin tu-
mors arising in parasympathetic ganglia. Paragangli-
omas usually develop in the head and the neck, most
commonly at the bifurcation of the carotid artery (i.e.,
at the carotid body). Up to 50% of paragangliomas
are familial, and three paraganglioma-susceptibility
loci are described herein: PGL1 (MIM 168000), which
results from SDHD mutations at 11q23; PGL2 (MIM
601650), which maps to 11q13, although the causative
gene has not been identified (Mariman et al. 1995);
and PGL3 (MIM 605373), which results from SDHC
mutations at 1q21 (Baysal et al. 2000; Niemann and
Muller 2000). SDHC and SDHD are the two subunits
of mitochondrial complex II, or succinate dehydrog-
50 Am. J. Hum. Genet. 69:49–54, 2001
enase (SDH), that anchor the other two subunits,
SDHA and SDHB, to the inner-mitochondrial mem-
brane. SDHA mutations are associated with juvenile
encephalopathy (Bourgeron et al. 1995), and the phe-
notypic consequences of SDHB mutations have not
been defined.
The occurrence of pheochromocytoma in some kin-
dreds with hereditary paragangliomas, as well as the
occasional reports of familial and isolated cases of both
pheochromocytoma and carotid-body tumors (MIM
115310) (Pritchett 1982; Jensen et al. 1991), have sug-
gested a possible etiological link. Recently, we described
germline SDHD mutations in patients presenting with
familial pheochromocytoma and in patients presenting
with isolated pheochromocytoma (Gimm et al. 2000;
Astuti et al. 2001). These findings prompted us to in-
vestigate familial and sporadic cases of pheochromocy-
toma and of paraganglioma, for mutations in the genes
encoding the SDHB and the SDHC components of SDH.
Subjects, Material, and Methods
Subjects and Tumor Material
In familial cases, blood was obtained from living af-
fected relatives available for investigation. Diagnoses of
familial cases were made according to the following cri-
teria: (a) the occurrence of pheochromocytoma in two
first-degree relatives, (b) the occurrence of pheochromo-
cytoma and head and neck paraganglioma in first-degree
relatives, and (c) the occurrence of pheochromocytoma
in three relatives in a single family. Previous investiga-
tions had excluded germline mutations in VHL, in
SDHD, and in MEN 2–associated regions of RET in
the familial cases (Woodward et al. 1997; Astuti et al.
2001). Twenty-four cases of sporadic pheochromocy-
toma were analyzed for mutations in SDHB and in
SDHC. In each case, tumor tissue and either correspond-
ing peripheral blood or adjacent normal adrenal tissue
were obtained at the time of surgery. Genomic DNAwas
then extracted from tumor tissue and from correspond-
ing normal tissue, according to standard procedures.
Ethical approval was obtained from the South Birming-
ham Ethics Committee and the appropriate institutional
review boards, and informed consent was received from
each patient.
SDHB and SDHC Mutation Analysis
For SDHC, the primer pairs for exon amplification
were as follows: 1F (5′-AAA ACA ACC AGC AAA CCA
GC-3′) and 1R (5′-CTC CCA GTC CCA CTG AAG TC-
3′), 2F (5′-TAC TTT TAA TCT ATC CCT TCA C-3′)
and 2R (5′-TCT CCA GAC TTA GAA ACT TA-3′), 3F
(5′-TTA TGC AAA ATA TTA AAC CAA GTT-3′) and
3R (5′-CTT ACC TGT AGA TAG TAA TGT GGG-3′),
4F (5′-TTA AAA TTG TCT TTG TGT GTT TCT-3′)
and 4R (5′-AAG AGA CTT ACT GTT CCC TCT AAA-
3′), 5F (5′-GGG GTC CCA GTT TTA TGT ATC A-3′)
and 5R (5′-CCT TCA CAG AGA AAA TGT GCA A-
3′), and 6F (5′- TGT TAA TGT CCT ATT TAC TGA
A-3′) and 6R (5′-TAA ACA AAT AAG GAG AAC TTT
T-3′). Primers were designed on the basis of the genomic
sequences. The amplicon sizes for SDHC exons 1, 2, 3,
4, 5, and 6 are 209, 178, 166, 215, 278, and 263 bp,
respectively (GenBank accession numbers AF039589,
AF039590, AF039591, AF039592, AF039593, and
AF039594, respectively).
For SDHB, the primer pairs for exon amplification
were as follows: 1F (5′-GCCGCTACTGCGCTATTG-
3′) and 1R (5′-GCT TTC CTG ACT TTT CCC-3′), 2F
(5′-TTT TTC CTT TTT GTG AAC TTT-3′) and 2R (5′-
AAG CAT GTC CCT AAA TCA AA-3′ ), 3F (5′-GAA
CTT TAC ATA AAT ACC ACT GGA-3′) and 3R (5′-
CTA TCA GCT TTG GCC AGC-3′), 4F (5′-ATG GGT
GAGGTG TGT TAA TG-3′) and 4R (5′-TGCAAATAA
AAA CAA AAC CA-3′), 5F (5′-TGA TGA TGG AAT
CTG ATC CT-3′) and 5R (5′-CAG ATT GAA ACA ATA
AAT AGG GA-3′), 6F (5′-CCT CTC TTT TCT CCC
CAT AC-3′) and 6R (5′-CAG CAA TCT ATT GTC CTC
TTG-3′), 7F (5′-AGC TAA TCA TCC CTG GTT TT-3′)
and 7R (5′-TTG TGA GCA CAT GCT ACT TC-3′), and
8F (5′-GTG GGT TTT CCC TTT CAG TT-3′) and 8R
(5′-CGG CAA GTA AAG GAA CAG GT-3′). Primers
were designed on the basis of the genomic sequences.
The amplicon sizes for SDHB exons 1, 2, 3, 4, 5, 6, 7,
and 8 are 320, 226, 200, 210, 175, 206, 216, and 319
bp, respectively (GenBank accession numbers U17296,
U17880, U17881, U17882, U17883, U17884, U17885,
and U17886, respectively; the GenBank accession num-
ber for SDHB cDNA is U17248).
By use of HotStar Taq (Qiagen), 50–100 ng of genomic
DNA was amplified in Omn-E thermal cyclers (Hybaid).
Amplification conditions were as follows: initial denatur-
ation at 95C for 10 min; then 35 cycles of 30 s of de-
naturation at 95C, 30 s of annealing at 55–60C, and
30 s of extension at 72C; and a final extension at 72C
for 5 min.
SSCP analysis was performed as described elsewhere
(Crossey et al. 1995). Aberrant amplicons were purified
using the QiaQuick gel extraction kit (Qiagen) before
being analyzed on the ABI377 DNA sequencer (Applied
Biosystems). For the 24 sporadic cases, both tumor and
blood DNA was analyzed by SSCP.
Haplotype and Loss of Heterozygosity (LOH) Analysis
The two polymorphic markers used for haplotype and
LOH analysis, D1S407 and D1S2647, flank SDHB
(D1S407 is ∼2.7 Mb telomeric, and D1S2647 is ∼1.8
Mb centromeric). Both markers were amplified using
Astuti et al.: SDHB Mutations in Familial Pheochromocytoma and in Familial Paraganglioma 51
Figure 1 Electropherograms, showing germline SDHBmutations (arrowheads), and simplified pedigrees for families K1–K3 (A) and family
K4 (B). The affected codon and the amino acids are depicted below the electropherograms. In pedigrees, symbols with horizontal bars indicate
pheochromocytoma (intra- or extra-adrenal), symbols with vertical bars indicate cervical paraganglioma, and symbols with checkered pattern
indicate both pheochromocytoma and paraganglioma.
standard PCR conditions. Amplicons were separated on
6% polyacrylamide denaturing gels, were visualized by
silver staining, and were exposed on an automatic-pro-
cessor–compatible film (Promega). LOHwas determined
by comparing the intensities of the alleles in heterozy-
gous samples of matched tumor and normal DNA. A
tumor was considered to have LOH in one of the alleles
if the ratio of the signal intensity in the tumor samples
differed at least twice as much as the signal intensity in
the corresponding normal sample. LOH analysis was not
performed for familial cases, because suitable material
was not available.
Results
Overall, we found four germline SDHB mutations, in
eight families segregating pheochromocytoma with or
without head and neck paraganglioma, and one occult
germline SDHB mutation, in 24 unrelated patients with
isolated pheochromocytoma. No pathogenic mutations
were identified in SDHC.
Familial Pheochromocytoma and Paraganglioma
We analyzed eight probands from kindreds with either
familial pheochromocytoma only ( ) or familialnp 5
pheochromocytoma with head and neck paraganglioma
( ). SSCP analysis of six exons constituting the cod-np 3
ing sequence of SDHC revealed only intronic single-nu-
cleotide polymorphisms that were also detected in con-
trols. Thus, there was no evidence of germline SDHC
mutations in the kindreds with familial pheochromocy-
toma and paraganglioma.
For SDHB mutations, we performed SSCP analysis of
the eight exons (281 amino acids) comprising the coding
sequence. First, we detected a CrT transition at nucle-
otide 402 in exon 3, in a Swedish three-generation fam-
ily, K1, with both extra-adrenal pheochromocytoma and
cervical paraganglioma, described elsewhere (Sko¨ldberg
et al. 1998) (see figs. 1A and 2). The 402CrT mutation
changes an arginine to a termination codon (R91X) and
was predicted to result in a truncated SDHB protein
lacking the C-terminal 191 amino acids; the R91X mu-
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Figure 2 Locations of germline mutations and missense substitution, detected in the highly conserved SDHB coding sequence (HS p
Homo sapiens; DM p Drosophila melanogaster). Multiple-sequence alignment was performed by the ClustalW program, available from BCM
Search Launcher. The mutations are shown with respect to the functional domains of the protein, as predicted by the InterPro program. The
black dots represent the four germline mutations described in the text. The yellow screen indicates the predicted ferredoxin domain (54–119
amino acids; GenBank accession number NP_002991), the green screen indicates the 2Fe-2S ferredoxin domain (93–101 amino acids), and the
blue screen indicates the 4Fe-4S ferredoxin iron-sulfur–binding domain (186–197 amino acids).
tation was not detected in 200 control chromosomes.
The R91X (402CrT) mutation was also detected in a
British family, K2, in which the proband presented with
extra-adrenal pheochromocytoma at the age of 10 years
and in which the proband’s mother had a cervical para-
ganglioma (i.e., a glomus jugiulare tumor) removed at
the age of 45 years; there was no other relevant family
history (see fig. 1A). An identical R91X (402CrT) mu-
tation was identified in another family, K3 (see fig. 1A),
in which two siblings developed early-onset pheochro-
mocytoma (i.e., onset at age !30 years).
Because the 402CrT mutation occurred at a hyper-
mutable CpG dinucleotide in three apparently unrelated
kindreds, we investigated the possibility of a founder mu-
tation, by haplotype analysis. Allelotyping at microsat-
ellite markersD1S407 andD1S2647, flanking SDHB,did
not show any shared alleles at D1S2647 (K1 included
two alleles, K2 included three or five alleles, and K3 in-
cluded four alleles) and did not show any common allele
at D1S407 (K1 included one or three alleles, K2 included
two or three alleles, and K3 included two alleles), sug-
gesting multiple de novo origins for the R91X mutation.
We also identified a germline SDHB mutation in an-
other kindred, K4, a large family containing three indi-
viduals with familial extra-adrenal pheochromocytoma
and without evidence of cervical paragangliomas (see figs.
1B and 2). An exon 6 SSCP bandshift was detected in
two affected members of K4. Sequence analysis demon-
strated a CrG transversion at nucleotide 724, causing a
proline-to-arginine missense mutation (P198R) (fig. 1B);
this changewas not detected in 200 control chromosomes.
This proline is conserved throughout all living species
analyzed—from human to rat,Drosophila, yeast, and Es-
cherichia coli (fig. 2).
Analysis of Sporadic Pheochromocytoma
Analysis of SDHB in matched blood and tumor DNA
from 24 cases of sporadic pheochromocytoma led to the
identification of two heterozygous sequence variants. In
case 1 (S1), an exon 6 frameshift deletion (725delC) was
present in blood and tumor DNA of a 55-year-old female
with a single adrenal pheochromocytoma and without
other significant personal or family history; this trun-
cating mutation was not observed in 200 control chro-
mosomes. Analysis of tumor DNA in S1 did not dem-
onstrate allele loss at either D1S407 or D1S2647. The
second sequence variant (394TrC, which causes an
L88S missense substitution) was detected in 1 of 200
control chromosomes and is therefore of uncertain sig-
nificance. No somatic or germline SDHC mutations
were detected in the 24 cases of sporadic pheochromocy-
toma analyzed.
Discussion
We have identified germline SDHB mutations in (a) in-
dividuals with familial pheochromocytoma, (b) individ-
uals with familial pheochromocytomaandparaganglioma
of the head and the neck, and (c) apparently sporadic
cases of pheochromocytoma. The phenotypic conse-
quences of germline mutations in each of the four com-
ponents of SDH have now been defined. It is interesting
that, whereas heterozygous mutations in SDHB (i.e., the
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gene for the iron-sulfur–protein subunit) and in both
SDHC and SDHD (i.e., the genes for the integral mem-
brane–protein subunits) are associated with neoplasia
(Baysal et al. 2000; Niemann and Muller 2000; present
study), autosomal recessive homozygous SDHA (i.e., the
gene for the flavoprotein subunit) mutations are associ-
ated with Leigh syndrome (MIM 600857) (Bourgeron et
al. 1995; Parfait et al. 2000).
The discovery of SDHB mutations in paraganglioma
and in pheochromocytoma further strengthens the link
between tumorigenesis and mitochondrial dysfunction.
Nevertheless, the precise mechanism by which muta-
tions in SDHB, in SDHC, and in SDHD predispose to
tumors derived from the autonomic nervous system is
uncertain. Germline mutations in the tumor-suppressor
gene VHL may predispose patients with mitochondrial
dysfunction to a variety of hypervascular tumors, in-
cluding pheochromocytoma (Kaelin and Maher 1998).
The product of the VHL gene has a critical role in the
regulation of hypoxia-responsive genes. Thus, VHL in-
activation, both in human cancers and in mousemodels,
results in up-regulation of angiogenic growth factors,
such as vascular endothelial growth factor, secondary
to a defect in ubiquitylation of the a-subunits of the
HIF-1 and the HIF-2 transcription factors (Maxwell et
al. 1999; Cockman et al. 2000; Ohh et al. 2000). How-
ever, although head and neck paragangliomas are hy-
pervascular, and although mitochondria have been im-
plicated in both oxygen sensing and regulation of HIF-1
expression, it is not certain that this can explain the
tumor susceptibility in patients with SDHB and SDHC
mutations. Interestingly, germline VHL mutations that
predispose patients to pheochromocytoma do not im-
pair HIF-1a ubiquitylation (Clifford et al. 2001; Hoff-
man et al. 2001). Another possible explanation for the
association between SDH-subunit mutations and neo-
plasia is the role of mitochondria in apoptosis—that is,
its role in the failure of apoptosis in autonomic-nervous-
system progenitor cells, which may result in the devel-
opment of paragangliomas and pheochromocytoma
(Cavalli and Liang 1998; Green and Reed 1998).
If failure of apoptosis in autonomic-nervous-system
progenitor cells is a relevant mechanism of SDHB-,
SDHC-, and SDHD-associated tumorigenesis, it might
be hypothesized that germline mutations in SDHB, in
SDHC, and in SDHD would be more frequent than
somatic mutations. Interestingly, in 62 cases of pheo-
chromocytoma, we identified only one somatic SDHD
mutation (Gimm et al. 2000; Astuti et al. 2001; Aguiar
et al., in press), and we did not identify any somatic
SDHB mutations. However, although somatic muta-
tions in SDHB and in SDHD are infrequent in cases of
pheochromocytoma, SDHD allele loss is frequent; epi-
genetic inactivation by promoter methylation has not
been investigated. Similarly, SDHB maps to 1p36, a
region of frequent allele loss in pheochromocytoma,
neuroblastoma, and other tumors, suggesting that fur-
ther analysis of SDHB in these tumor types is needed
(Benn et al. 2000; Nomoto et al. 2000).
Familial paragangliomas caused by SDHD mutations
demonstrate genomic-imprinting effects, and, conse-
quently, a disease phenotype is manifested only after pa-
ternal transmission. However, examination of the phe-
notypic expression of (a) germline SDHB mutations,
reported herein, and (b) SDHC mutations, reported by
Niemann and Muller (2000), does not reveal parent-of-
origin effects, which would be clinical evidence for ge-
nomic imprinting of these genes. To date, no genotype-
phenotype correlations that would explain the variable
phenotype of germline mutations in SDHB and in SDHD
are apparent, and genetic or environmental modifiers
may be implicated. We have detected occult germline
mutations in SDHB and in SDHD, in patients with ap-
parently isolated pheochromocytoma; ∼8% of isolated
cases of pheochromocytoma that have been tested have
had unsuspected germline mutations in one of these two
genes, although frequency estimates are based on small
numbers. These findings have important implications for
the management of patients with pheochromocytoma
(because of the risk of further intra- and extra-adrenal
pheochromocytomas and cervical paragangliomas, in
susceptible individuals) and suggest that routine genetic
screening may be warranted.
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